Bnp Paribas Asset Management Holding S.A. Crinetics Pharmaceuticals, Inc. Transaction History
Bnp Paribas Asset Management Holding S.A.
- $37.3 Billion
- Q1 2025
A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 610,839 shares of CRNX stock, worth $18.9 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
610,839
Previous 576,068
6.04%
Holding current value
$18.9 Million
Previous $29.5 Million
30.44%
% of portfolio
0.05%
Previous 0.07%
Shares
11 transactions
Others Institutions Holding CRNX
# of Institutions
230Shares Held
87.1MCall Options Held
40KPut Options Held
162K-
Vanguard Group Inc Valley Forge, PA9.31MShares$289 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.89MShares$214 Million0.05% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.24MShares$193 Million2.28% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$193 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.11MShares$158 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.67B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...